SCHEMBL2811498

SCHEMBL2811498

Cc1ccc(COC(=O)N2CCN(c3nc(C(=O)Nc4ccc5[nH]nnc5c4)cs3)CC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
LMNA P02545 4/20 0.42
NPSR1 Q6W5P4 2/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KMT2A Q03164 5/20 0.39
CTNNB1 P35222 2/20 0.38
TCF7L2 Q9NQB0 2/20 0.38
GAA P10253 3/20 0.38
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.38
CASP1 P29466 1/20 0.38
ATM Q13315 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NPC1 O15118 1/20 0.37
TP53 P04637 2/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2810311 0.94 MAPT (0.42) MAPTLMNANPSR1TSHRMAPK1
SCHEMBL2805530 0.93 MAPT (0.46) MAPTLMNANPSR1TSHRMAPK1
SCHEMBL2806745 0.92 MAPT (0.45) MAPTLMNANPSR1TSHRMAPK1
SCHEMBL2810120 0.92 MAPT (0.38) MAPTLMNANPSR1TSHRMAPK1
SCHEMBL2805505 0.91 LMNA (0.43) MAPTLMNANPSR1TSHR
SCHEMBL2810678 0.90 ENPP2 (0.40) MAPTLMNANPSR1TSHRMAPK1
SCHEMBL2809858 0.90 ENPP2 (0.43) MAPTLMNANPSR1TSHRMAPK1
SCHEMBL2809795 0.88 MAPT (0.35) MAPTLMNANPSR1TSHRMAPK1
SCHEMBL13129753 0.84 NAMPT (0.46) MAPTNPSR1TSHRSMN1; SMN2KMT2A
SCHEMBL2806588 0.83 ENPP2 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2209777-B1 THIAZOL DERIVATIVES FOR TREATING CANCER MERCK PATENT GMBH (DE) 2015-07-29 EP claimed
US-8557824-B2 Thiazole derivatives MERCK PATENT GMBH (DE) 2013-10-15 US claimed
US-20100240676-A1 THIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240676-A1 THIAZOLE DERIVATIVES CCNE2, PKD1, PKD2 MAPT 1450/4885LMNA 1974/4885NPSR1 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.